![\"\"](\"https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/kucuk-molekul-ilac-devrimi-deucravacitinib-tyk2-inhibitoru-nedir-nasil-calisir-ve-kimler-icin-umut-vadediyor-detail-content.png\")
<\/p>\n<\/p>\n
<\/p>\n
Baz\u0131 ila\u00e7lar vard\u0131r; yaln\u0131zca bir hastal\u0131\u011f\u0131n semptomlar\u0131n\u0131 hafifletmekle kalmaz, ayn\u0131 zamanda \u201chedefe y\u00f6nelik tedavi\u201d kavram\u0131n\u0131 daha eri\u015filebilir hale getirir. Deucravacitinib<\/strong> tam olarak bu s\u0131n\u0131fa g\u00f6z k\u0131rpan, a\u011f\u0131zdan al\u0131nan bir k\u00fc\u00e7\u00fck molek\u00fcl TYK2 inhibit\u00f6r\u00fc<\/strong>. \u00d6zellikle ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin a\u015f\u0131r\u0131 \u00e7al\u0131\u015ft\u0131\u011f\u0131 hastal\u0131klarda, \u201cetkili ama daha se\u00e7ici\u201d bir yakla\u015f\u0131m arayanlar\u0131n radar\u0131na girdi. Peki deucravacitinib nedir, nas\u0131l \u00e7al\u0131\u015f\u0131r ve kimler i\u00e7in umut vadediyor?<\/p>\n Deucravacitinib, TYK2 (Tyrosine Kinase 2)<\/strong> adl\u0131 sinyal iletim proteinini hedefleyen, a\u011f\u0131zdan kullan\u0131lan bir k\u00fc\u00e7\u00fck molek\u00fcld\u00fcr. TYK2; IL\u201112, IL\u201123 ve Tip I interferon<\/strong> gibi ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131nda kritik rol oynayan sitokinlerin sinyallerini ileten JAK ailesiyle ili\u015fkili bir kinazd\u0131r. Bu nedenle TYK2\u2019nin kontroll\u00fc bi\u00e7imde bask\u0131lanmas\u0131, otoimm\u00fcn ve inflamatuvar<\/strong> hastal\u0131klarda klinik fayda sa\u011flayabilir.<\/p>\n Klasik JAK inhibit\u00f6rleri \u00e7o\u011funlukla kinaz\u0131n aktif b\u00f6lgesine (ATP ba\u011flanma b\u00f6lgesi) ba\u011flanarak etki eder. Deucravacitinib\u2019in dikkat \u00e7ekici yan\u0131 ise TYK2\u2019nin ps\u00f6dokinaz (JH2) d\u00fczenleyici domenine<\/strong> ba\u011flanmas\u0131d\u0131r. Bu allosterik ba\u011flanma, TYK2\u2019yi \u201ckapal\u0131\u201d konumda tutarak sinyal iletimini azalt\u0131r. Bu yakla\u015f\u0131m\u0131n teorik avantaj\u0131, JAK1\/2\/3 \u00fczerinde daha az istenmeyen etkiyle daha y\u00fcksek hedef se\u00e7icili\u011fi<\/strong> yakalayabilmesidir. Mekanizman\u0131n ayr\u0131nt\u0131lar\u0131 i\u00e7in bkz: https:\/\/doi.org\/10.1126\/science.aaw4367<\/a><\/p>\n Deucravacitinib \u00f6zellikle orta-\u015fiddetli plak tip sedef hastal\u0131\u011f\u0131 (psoriasis)<\/strong> alan\u0131nda g\u00fc\u00e7l\u00fc klinik verilerle g\u00fcndeme geldi. TYK2\u2019nin IL\u201123\/IL\u201112 eksenindeki rol\u00fc d\u00fc\u015f\u00fcn\u00fcld\u00fc\u011f\u00fcnde, bu sonu\u00e7lar biyolojik olarak da tutarl\u0131. Klinik etkinlik verileri ve kar\u015f\u0131la\u015ft\u0131rmal\u0131 sonu\u00e7lar i\u00e7in \u00f6nemli bir kaynak: https:\/\/doi.org\/10.1056\/NEJMoa2114883<\/a><\/p>\n Elbette her imm\u00fcn mod\u00fclat\u00f6rde oldu\u011fu gibi, enfeksiyon riski ve bireysel komorbiditeler gibi fakt\u00f6rler hekimin de\u011ferlendirmesinde belirleyicidir. Bu yaz\u0131 tedavi \u00f6nerisi de\u011fildir; amac\u0131m\u0131z mekanizmay\u0131 anla\u015f\u0131l\u0131r k\u0131lmak ve \u201cneden bu ila\u00e7 konu\u015fuluyor?\u201d sorusuna net yan\u0131t vermektir.<\/p>\n Deucravacitinib\u2019in hik\u00e2yesi, k\u00fc\u00e7\u00fck molek\u00fcllerin art\u0131k yaln\u0131zca \u201cgenel bask\u0131lay\u0131c\u0131\u201d de\u011fil; allosterik, se\u00e7ici ve ak\u0131ll\u0131 tasar\u0131ml\u0131<\/strong> hedefleyiciler olabildi\u011fini g\u00f6steriyor. TYK2\u2019nin d\u00fczenleyici domenini hedeflemek, ila\u00e7 ke\u015ffinde \u201cayn\u0131 protein, farkl\u0131 kilit\u201d fikrinin ne kadar de\u011ferli oldu\u011funu kan\u0131tlayan \u00f6rneklerden biri.<\/p>\n \u00d6zellikle orta-\u015fiddetli plak tip psoriasis<\/strong> tedavisinde \u00f6ne \u00e7\u0131kan, TYK2\u2019yi hedefleyen a\u011f\u0131zdan al\u0131nan k\u00fc\u00e7\u00fck molek\u00fcl bir ila\u00e7t\u0131r. Kullan\u0131m alanlar\u0131 \u00fclkeye ve onaylara g\u00f6re de\u011fi\u015febilir.<\/p>\n TYK2, ba\u011f\u0131\u015f\u0131kl\u0131k sinyallerini ileten bir kinazd\u0131r. TYK2 inhibit\u00f6r\u00fc<\/strong> ise bu sinyali azaltarak inflamasyonu d\u00fc\u015f\u00fcrmeyi hedefleyen ila\u00e7 s\u0131n\u0131f\u0131n\u0131 ifade eder.<\/p>\n TYK2, JAK ailesiyle ili\u015fkilidir; ancak deucravacitinib klasik JAK inhibit\u00f6rlerinden farkl\u0131 olarak TYK2\u2019nin d\u00fczenleyici (ps\u00f6dokinaz) domenine<\/strong> allosterik ba\u011flan\u0131r ve bu sayede daha se\u00e7ici bir profil hedefler.<\/p>\n Hay\u0131r. K\u00fc\u00e7\u00fck molek\u00fcl<\/strong> bir ila\u00e7t\u0131r ve a\u011f\u0131zdan al\u0131n\u0131r. Biyolojik ila\u00e7lar genellikle b\u00fcy\u00fck protein yap\u0131l\u0131 ve \u00e7o\u011funlukla enjeksiyonla uygulan\u0131r.<\/p>\n En \u00e7ok konu\u015fulan avantaj\u0131, TYK2\u2019yi allosterik ve se\u00e7ici<\/strong> bi\u00e7imde hedefleyerek etkili bir imm\u00fcn mod\u00fclasyon sa\u011flamay\u0131 ama\u00e7lamas\u0131 ve a\u011f\u0131zdan kullan\u0131m<\/strong> kolayl\u0131\u011f\u0131 sunmas\u0131d\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":" Deucravacitinib, a\u011f\u0131zdan kullan\u0131lan se\u00e7ici bir TYK2 inhibit\u00f6r\u00fcd\u00fcr. JAK\u2019lardan fark\u0131, ps\u00f6dokinaz (JH2) domenine allosterik ba\u011flanmas\u0131d\u0131r. Psoriasis ve otoimm\u00fcn hastal\u0131klarda nas\u0131l \u00e7al\u0131\u015f\u0131r, kimler i\u00e7in uygundur?<\/p>\n","protected":false},"author":1,"featured_media":10408,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[122],"tags":[926,928,927],"class_list":["post-10407","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-molekul","tag-deucravacitinib","tag-psoriasis-tedavisi","tag-tyk2-inhibitoru"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10407"}],"version-history":[{"count":3,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10407\/revisions"}],"predecessor-version":[{"id":10412,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10407\/revisions\/10412"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/media\/10408"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Deucravacitinib nedir?<\/h2>\n
Nas\u0131l \u00e7al\u0131\u015f\u0131r? \u201cOrtopedik\u201d bir se\u00e7icilik: JAK\u2019lardan fark\u0131<\/h2>\n
Hangi hastal\u0131klarda \u00f6ne \u00e7\u0131k\u0131yor?<\/h2>\n
Kimler i\u00e7in umut vadediyor?<\/h2>\n
\n
Neden \u201ck\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7 devrimi\u201d i\u00e7inde an\u0131l\u0131yor?<\/h2>\n
Referanslar<\/h2>\n
\n
Soru-Cevap: Google\u2019da en \u00e7ok aranan 5 soru<\/h2>\n
1) Deucravacitinib ne i\u00e7in kullan\u0131l\u0131r?<\/h3>\n
2) TYK2 inhibit\u00f6r\u00fc ne demek?<\/h3>\n
3) Deucravacitinib JAK inhibit\u00f6r\u00fc m\u00fc?<\/h3>\n
4) Deucravacitinib biyolojik ila\u00e7 m\u0131?<\/h3>\n
5) Deucravacitinib\u2019in en \u00f6nemli avantaj\u0131 nedir?<\/h3>\n